Your browser does not support JavaScript capabilities, which maybe required to display this page properly.


PDF FormatRequires Adobe Acrobat Reader

Table 6.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1998 to 2007

Recipients with Pancreas Transplant Alone (PTA) Transplants

  Year of Transplant
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
Transplants 88 139 134 168 181 160 183 199 173 208
Tx with Antirejection Treatments 20 30 28 20 36 31 34 31 23 37
Antibodies Any in Category 55.0% 90.0% 92.9% 65.0% 63.9% 77.4% 55.9% 51.6% 39.1% 54.1%
Atgam/NRATG/NRATS 10.0% 0.0% 0.0% 5.0% 0.0% 0.0% 2.9% 0.0% 0.0% 0.0%
OKT3 50.0% 73.3% 57.1% 30.0% 38.9% 25.8% 20.6% 25.8% 21.7% 16.2%
Thymoglobulin 10.0% 40.0% 57.1% 40.0% 36.1% 54.8% 26.5% 35.5% 13.0% 40.5%
Zenapax 0.0% 13.3% 3.6% 5.0% 2.8% 9.7% 2.9% 0.0% 4.3% 2.7%
Simulect 0.0% 3.3% 3.6% 5.0% 0.0% 0.0% 0.0% 0.0% 4.3% 0.0%
Campath 0.0% 0.0% 0.0% 0.0% 11.1% 38.7% 26.5% 3.2% 0.0% 0.0%
Corticosteroids Any in Category 70.0% 73.3% 78.6% 90.0% 86.1% 80.6% 85.3% 83.9% 95.7% 94.6%
Steroids 70.0% 73.3% 78.6% 90.0% 86.1% 80.6% 85.3% 83.9% 95.7% 94.6%
Antimetabolites Any in Category 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Methotrexate 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%


Source: OPTN/SRTR Data as of May 4, 2009.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.



PDF FormatRequires Adobe Acrobat Reader